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Introduction {#sec0005}
============

Chagas disease is a potentially life-threatening endemic illness in the Latin America region ([@bib0020], [@bib0165]). It is caused by a protozoan parasite called *Trypanosoma cruzi*. This parasite has been classified into six genetic variants with approximate geographical distribution in domestic and wild transmission cycles ([@bib0270]). It is mainly transmitted through vectors (namely triatomine bugs) in impoverished rural areas ([@bib0100], [@bib0165]). Blood transfusion and congenital transmission are other mechanisms for acquiring the disease. Alternative mechanisms are accidental, oral, and via organ transplantation ([@bib0055], [@bib0140]).

The duration and clinical presentation of the initial acute phase of the infection may be variable, depending on the patient's age, immunological status, presence of comorbidities, and the transmission pathway. It usually lasts a few months and may be symptomatic (prolonged febrile syndrome, asthenia, hepatosplenomegaly, and other characteristic but less frequent signs, such as Romaña sign and 'chagoma' of inoculation) or asymptomatic ([@bib0140]).

Most subjects who do not receive specific treatment during the acute phase go on to develop a chronic infection. If untreated, the chronic phase usually continues for the subject's lifetime, and 30% to 40% of patients will progress to the chronic phase with a cardiac, digestive, neurological, or mixed form at 15 to 30 years after the initial infection. Progressive heart failure and sudden death are the main causes of death in patients with chronic Chagas heart disease ([@bib0140], [@bib0165]).

Several systematic reviews on the effectiveness of treatment in chronically infected subjects have been published ([@bib0260], [@bib0080], [@bib0170], [@bib0245]). The current recommendation of the World Health Organization (WHO) is to offer anti-trypanosomal drugs (benznidazole or nifurtimox) to subjects with chronic *Trypanosoma cruzi* infection, particularly those who are asymptomatic ([@bib0020]). Based on current techniques and their attributes, the general consensus is that treatment success is confirmed by conversion from a positive to a negative serological state (seroreversion), while treatment failure is demonstrated through a positive molecular or parasitological test. The assessment of the response to treatment is uncertain in a large number of subjects because of the long span needed to demonstrate the disappearance of anti-*T. cruzi* antibodies ([@bib0040], [@bib0265]).

In this context, it was sought to answer the following question: When and to what extent does the administration of anti-trypanosomal drugs result in the negativization of serological tests through the course of follow-up? The present research group previously published a prognostic systematic review of follow-up studies including chronically infected and treated subjects as a first attempt to address the research question. The results of that review showed a dynamic pattern of serological response; however, pre-planned secondary analyses were incomplete due to the limited utility of aggregate data ([@bib0200]). As a consequence, a meta-analysis of individual participant data (IPD) was conducted considering all laboratory tests performed after treatment ([@bib0180], [@bib0230]). The purpose of this article is to present the course of serological tests and describe the effect of explanatory factors on the time to seroreversion in treated subjects with chronic *Trypanosoma cruzi* infection. The hypothesis was based on previous research suggesting an earlier reversion of conventional serology to negative results in treated subjects with an 'early chronic infection' (children and adolescents) compared to those with a 'late chronic infection' (adults).

Methods {#sec0010}
=======

Study design {#sec0015}
------------

This meta-analysis was performed according to the protocol registered in the international database of prospectively registered systematic reviews, PROSPERO (<http://www.crd.york.ac.uk/PROSPERO>, registration number CRD42012002162) in March 2012 ([@bib0195]). All studies shared unidentified data; hence individual consent for the reuse of participant data was not sought.

The inclusion and exclusion criteria have been detailed elsewhere ([@bib0200]). Cohort studies and randomized controlled trials (RCTs) with follow-up data on serological, molecular, and parasitological outcomes measured in subjects with a definite diagnosis of chronic *Trypanosoma cruzi* infection, who received benznidazole and/or nifurtimox, were included. Subjects in the acute phase, children aged 12 months or younger born to infected mothers, immunocompromised participants, and pregnant women were excluded. Two authors, one with training in systematic reviews (YS) and one expert in the field (SSE), identified potentially eligible studies. YS also screened the references of relevant studies. Disagreements were resolved by discussion. The electronic search strategies used have been described previously; there was no restriction on language or year of publication ([@bib0200]).

The electronic searches in the Cochrane Database of Systematic Reviews (CDSR), Cochrane Central Register of Controlled Trials (CENTRAL), Database of Abstracts of Reviews of Effects (DARE), MEDLINE (Supplementary Material, Annex A, Table S1), Embase, and LILACS were updated on July 1, 2015. Three new eligible studies were identified ([@bib0015], [@bib0010], [@bib0050]). In addition, the protocol was presented to experts in the field and three further studies were identified by contacting the principal investigators ([@bib0150], [@bib0110], [@bib0085]).

Two review authors (YS and AC) independently assessed the risk of bias of included studies using the tools recommended by the Cochrane Collaboration ([@bib0095], [@bib0225]). A data extraction template with the following principal domains of bias was used: selection of participants into the study, measurement of the intervention, measurement of outcomes, and missing data. The judgment regarding the overall risk of bias for each serological outcome was rated as low, moderate, or high. Studies with a low risk of bias for all key domains or studies where it seemed unlikely that bias would have altered the results were considered to have a low risk of bias. Studies with a risk of bias in at least one domain were considered to have an overall risk matching the higher level of bias identified that decreases the grade of certainty. Discrepancies were resolved through discussion with a third author (SSE).

Outcomes {#sec0020}
--------

Primary outcomes were the results of conventional serological tests, such as the enzyme-linked immunosorbent assay (ELISA), indirect immunofluorescence (IIF) assay, and indirect hemagglutination assay (IHA). Secondary outcomes were the results of non-conventional 'in-house' serological tests based on recombinant/synthetic or biochemically purified antigens specifically used to monitor changes after anti-trypanosomal treatment. The results of serological tests were dichotomized as reactive or non-reactive (negative result) independently of each other. It was decided to analyze the techniques separately given the variability of their performance in demonstrating serological changes over time. The dependent variable was defined as the time elapsed from the end of treatment to the first negative result of each serological test as measured by the authors. No composite outcomes were defined at the protocol stage.

Data collection {#sec0025}
---------------

A systematic approach to request, collect, and manage IPD was undertaken ([@bib0230]). All corresponding or primary authors were invited to participate in this research by e-mail. In the case of a non-response, the contact details were checked and the website of universities or other research organizations explored to find a new e-mail address. At least three rounds of e-mails per investigator were launched by the same person (YS). In some cases, a member of the review team (SSE) sent a letter of invitation or made a phone call. The strategy developed had three basic steps. The first e-mail intended to present the research and provided a link to the systematic review protocol. The importance of the meta-analytical approach was explained in brief and the investigators were invited to participate. A second e-mail was sent to those collaborators expressing their willingness to contribute; this e-mail included a link to a short online survey aimed at gathering baseline information (availability of primary study protocol, the format of the study dataset, the time needed to send the original data, etc.), and a section to update their contact details. Following this, a third e-mail was sent that included a detailed description of the piece of information needed for each outcome of interest, an agreement on data security and co-authorship to be signed, and recommendations for encrypted data sharing.

Concerning the variables of interest, collaborators provided individual-level data at baseline (sex, age at treatment, age at study entry, country of origin, the name of the anti-trypanosomal drug, the dose and length of treatment) and during the follow-up (dates of measurements and results of all available laboratory tests). The internal consistency of IPD for each study dataset was checked independently by two authors (YS and KR), taking into account the information published in the original reports. Minor queries were resolved by reaching a consensus; however, any specific IPD inconsistency was resolved by seeking clarification from the collaborators (YS). Any inaccuracies or errors were properly discussed and all amendments were registered before merging a study dataset into the master file (YS and KR). Missing data were also requested, whenever appropriate (YS). All collaborators answered an e-mail about the risk of reinfection in their study population.

Statistical analysis {#sec0030}
--------------------

The one-stage IPD meta-analysis was followed as stated at the protocol stage. Two functions that are dependent on time for describing the distribution of event times (the survival and hazard functions) were estimated ([@bib0175], [@bib0025]). The Kaplan--Meier method was used to obtain univariate descriptive survival data on two or more groups of subjects ([@bib0025]). The Cox proportional hazards regression model with random effects was applied to adjust for pre-specified covariates of clinical relevance. In this model, the time was assembled in years as provided in most datasets. The excess risk or frailty for distinct studies was described using the variance component of random effects and the corresponding Kendall's Tau coefficient ($\widehat{\tau}$) ([@bib0240]). Hazard ratios (HR) and 95% confidence intervals (CI) were calculated.

Subgroup analyses were performed based on potential predictors of treatment response in the chronic phase of *Trypanosoma cruzi* infection, such as the age of the subject at treatment (children/adolescents vs. adults) and the country where the subject was born, as a surrogate for the lineage of the parasite (Argentina, Bolivia, Chile, and Paraguay vs. Brazil) ([@bib0270]).

Taking advantage of available IPD on polymerase chain reaction (PCR) or xenodiagnosis after treatment, the study participants were assigned to the following three post-hoc categories: 'potential responders', i.e. subjects with three or more negative PCR or xenodiagnosis results; 'uncertain responders', i.e. subjects with at least two negative PCR or xenodiagnosis results; and 'non-responders/potential non-responders', i.e. subjects with just one PCR or xenodiagnosis (positive or negative).

The effect of the risk of bias was explored through a sensitivity analysis. The survival analyses for this study were done using SAS version 9.4. A *p*-value of less than 0.05 was considered statistically significant. It was not possible to use aggregate data from studies for which IPD were not obtained because time-to-event analysis requires individual-level data.

Results {#sec0035}
=======

A total of 24 cohort studies and three RCTs (1296 subjects) reporting on serological outcomes were included ([Figure 1](#fig0005){ref-type="fig"}; [Table 1](#tbl0005){ref-type="table"}) ([@bib0110], [@bib0145], [@bib0065], [@bib0105], [@bib0120], [@bib0155], [@bib0185], [@bib0005], [@bib0115], [@bib0090], [@bib0160], [@bib0045], [@bib0060], [@bib0070], [@bib0220], [@bib0190], [@bib0035], [@bib0255], [@bib0130], [@bib0235], [@bib0250], [@bib0210], [@bib0205], [@bib0030], [@bib0125]). For studies conducted before the 1990s or for which the primary author had died, no attempt to obtain original raw data was made. It was not possible to obtain IPD from 21 cohort studies ([Figure 1](#fig0005){ref-type="fig"}); some of them are known to be lost (Supplementary Material, Annex B). Three eligible studies involving children could be reachable in the future: two studies were from Colombia (*n* = 79) and reported up to 42.0% of seroreversion after 30 months of treatment, and one was from Brazil (*n* = 46), which reported almost 20.0% of seroreversion after 24 months of follow-up. Regarding the studies conducted in adults that may still be accessible, the published rate of seroreversion ranged from 5% after 5--10 years of treatment to 45.0% in just one cohort study reporting on 55 treated subjects living in a non-endemic area after more than 20 years of follow-up (Supplementary Material, Annex A, Table S2).Figure 1PRISMA IPD flow diagram.¶One multi-country study including four cohorts of children. \*Number obtained from published reports. ^♣^A subject could have more than one reason for exclusion. IPD, individual participant data; RCT, randomized controlled trial.Figure 1Table 1Studies for which individual participant data on serological outcomes was provided, categorized by country, duration of follow-up, area of endemicity, treatment, and type of test (27 studies, 1296 treated subjects with chronic *Trypanosoma cruzi* infection).Table 1SourceStudy ID[a](#tblfn0005){ref-type="table-fn"}Maximum duration follow-up (months)Area of endemicityRisk of reinfectionAge at treatment (years)Anti-trypanosomal drugNumber of treated subjects with IPD for time-to-event analysisTotal number of subjects with serology[b](#tblfn0010){ref-type="table-fn"}Parasitological testsConventional serological testNon-conventional serological testXDPCRELISAIIFIHA**Argentina**[@bib0110]69YesNo16--34Benznidazole--5238--39--39[@bib0065]401NoNo6--45Benznidazole and Nifurtimox----475252--52[@bib0185]60YesNo3--16Benznidazole--4545--45--45[@bib0235]288NoNo1--14Benznidazole and Nifurtimox21--264848--48[@bib0220]144YesNo6--14Benznidazole----16161616--[@bib0215]4849465353525353[@bib0190]66YesNo19--41Benznidazole----18--181818**Total number of subjects -- Argentina255Brazil**[@bib0120]156YesNo6--37Benznidazole--2726----2226[@bib0045][@bib0005]348YesNo8--56Benznidazole--292929----29[@bib0115]432YesNo2--60Benznidazole--949494949494Hassslocher-Moreno (2010)204NoNo16--56Benznidazole62----62----62[@bib0070]36YesNo17--48Benznidazole--808080----80[@bib0035]44YesNK23--76Benznidazole--37373737--37[@bib0130]50YesNo10--61Benznidazole--3131--31--31[@bib0205]204YesNK7--12Benznidazole and Nifurtimox3828373737--37[@bib0030]36YesNo8--11Benznidazole----5858585858**Total number of subjects -- Brazil454Bolivia**[@bib0075]12YesNo5--10Benznidazole22333322--3333**Total number of subjects -- Bolivia33Chile**[@bib0155]57YesNo22--48Nifurtimox2121--21----21[@bib0210]36YesNo1--10Nifurtimox373737--37--37**Total number of subjects -- Chile58**Honduras[@bib0060]51YesNo1--18Benznidazole----227------227**Total number of subjects -- Honduras227Paraguay**[@bib0255]120YesNo9--11Benznidazole----55----5[@bib0250]24YesNo7--14Benznidazole20202020----20[@bib0125]**Total number of subjects -- Paraguay25Spain**[@bib0145]12NoNo27--60Benznidazole--2526------26[@bib0160]30NoNo2--74Benznidazole--138181181----181**Total number of subjects -- Spain207Switzerland**[@bib0105]36NoNo25--59Nifurtimox--3737------37**Total number of subjects -- Switzerland37Grand total1296**[^1][^2][^3]

The total available follow-up for serological outcomes was 6847 person-years (median 3.0 years per person, interquartile range 1.5--7.0 years). Benznidazole was used as the only treatment of choice in 24 out of 27 included studies. The most common duration of treatment was 31 to 60 days (959 subjects) (Supplementary Material, Annex A, Table S3). Most of the included studies reported at least two serological tests. Non-conventional serology results were provided in seven studies and molecular or parasitological test results were provided in 20 studies ([Table 1](#tbl0005){ref-type="table"}). The risk of bias was low for all domains in 17 studies (63.0%), moderate in five (18.5%), and high in another five (Supplementary Material, Annex A, Figure S1).

No issues were encountered when checking IPD integrity. The highest rate of missing IPD was around 15.0% for ELISA. Sample sizes beyond 10 years of follow-up were small. The approach used for measuring the variation among studies revealed that $\widehat{\tau}$ was 0.63 for ELISA, 0.58 for IIF, and 0.47 for IHA.

A total 913 subjects (149 seroreversion events, 83.7% censored data) were assessed for ELISA, 670 subjects (134 events, 80.0% censored data) for IIF, and 548 subjects (99 events, 82.0% censored data) for IHA. A higher probability of seroreversion was observed within a shorter time span in treated subjects aged 1--19 years compared to adults. In this respect, after 11--13 years of follow-up, there was a 0.50 probability of seroreversion in the subgroup of treated children and adolescents living in Argentina, Bolivia, Chile, and Paraguay. When considering the same time after treatment for the subgroup of Brazilian children and adolescents, a similar probability of 0.55 was observed for the ELISA test. In subjects treated as adults, the probability of seroreversion after 11 years of treatment was around 0.90 ([Figure 2](#fig0010){ref-type="fig"}). There were no statistically significant differences in the risk of seroreversion between female and male subjects for any of the serological tests (data not shown).Figure 2Kaplan--Meier plots of the progression of conventional serology in treated subjects with chronic *Trypanosoma cruzi* infection stratified by age at treatment and country setting, with 95% confidence intervals. Plots show the proportion of treated subjects progressing towards seroreversion according to (1) ELISA, (2) IIF, and (3) IHA tests during the follow-up, stratified by age at treatment (1--19 years vs. \>19 years) and country setting (group A: Argentina, Bolivia, Chile and Paraguay vs. group B: Brazil).ELISA, enzyme-linked immunosorbent assay; IIF, indirect immunofluorescence assay; IHA, indirect hemagglutination assay.Figure 2

By using non-conventional serology test results, an earlier probability of seroreversion could also be inferred compared to conventional serology in children and adolescents (Supplementary Material, Annex A, Table S4 and Figure S2). No statistically significant difference among survival curves stratified by category using available PCR or xenodiagnosis IPD was found (Supplementary Material, Annex A, Table S5 and Figure S3).

The adjusted Cox model demonstrated the interaction between age at treatment and country setting. The pooled adjusted HR between subjects aged 1--19 years at treatment in comparison to adults varied according to the country where the infection might have been acquired. In the region of Brazil, a higher chance of seroreversion was found in children and adolescents compared to adults: HR 6.60 (95% CI 2.03--21.42) for ELISA, HR 9.37 (95% CI 3.44--25.50) for IIF, and HR 5.55 (95% CI 1.46--21.11) for IHA. No statistically significant differences were found for this comparison in Argentina, Bolivia, Chile, and Paraguay ([Table 2](#tbl0010){ref-type="table"}). The sensitivity analysis was not informative (Supplementary Material, Annex A, Table S6).Table 2Hazard ratios (95% confidence intervals) corresponding to the adjusted Cox interaction model for conventional serology in treated children or adolescents (1--19 years) versus adults (\>19 years) with chronic *Trypanosoma cruzi* infection.Table 2Serological testHR (95% CI)*p*-value[a](#tblfn0015){ref-type="table-fn"}BrazilArgentina, Bolivia, Chile, and ParaguayELISA6.60 (2.03--2.42)1.71 (0.77--3.81)0.062IIF9.37 (3.44--25.50)1.54 (0.64--3.71)0.007IHA5.55 (1.46--21.11)1.09 (0.44--2.70)0.047[^4][^5]

Discussion {#sec0040}
==========

This appears to be the first meta-analysis using IPD in subjects with chronic *Trypanosoma cruzi* infection who had received anti-trypanosomal drugs. The results provide an improved picture of the kinetics of anti-*T. cruzi* antibodies in different country settings and show that the serological course after treatment is variable along the duration of follow-up, as reported previously ([@bib0040], [@bib0265]). Nevertheless, the single-arm study design poses limitations with regard to the inferences that can be drawn from this meta-analysis. This approach relates directly to the aim of the research and the preliminary published results showing scatter plots of negative serological tests in non-treated subjects with chronic *Trypanosoma cruzi* infection based on aggregate data ([@bib0200]). The techniques used to measure the serological course presented differences that could be explained by the affinity during the formation of the antigen--antibody complex, with the ELISA test performing better for the detection of seroreversion. This phenomenon has been described before in two RCTs in the medium-term ([@bib0030]). Non-conventional serological tests seem to detect early the disappearance of antibodies after treatment in children and adolescents compared to ELISA, IIF and IHA tests.

Possible patterns of interaction with the probability of occurrence of seroreversion were explored. The age at treatment and the country setting are two variables that merit further attention when assessing treatment success during the chronic phase. Whereas a positive molecular or parasitological test confirms the failure of treatment, a negative result cannot rule out the absence of infection because of the lack of sensitivity in the chronic phase of Chagas disease. The pattern of serology shown according to the number and results of available PCR or xenodiagnosis tests merits a more comprehensive assessment. The preliminary observations suggested a better course in treated subjects with persistent parasite clearance measured by three or more negative PCR or xenodiagnosis tests after treatment. Among other plausible explanations, seroreversion in subjects classified as 'non-responders/potential non-responders' might be explained by the transient nature of the PCR results and by the conservative approach adopted to define the categories on a post-hoc basis.

This study has the following strengths. A pragmatic approach was taken in adopting the current recommendations for IPD meta-analysis (Supplementary Material, Annex C). The rate of response to the invitation to participate was high and most of the studies for which IPD were not provided included adults. The risk of bias assessment was restricted to those domains that were relevant to the meta-analysis. Included studies benefited from a well-defined intervention status and objective outcome measures, hence the measurement of interventions and the measurement of outcomes were judged as having a low risk of bias in all studies. A pilot test was conducted for the selection of the statistical methodology to ensure a rigorous IPD analysis.

This study has some limitations. To be relevant, a meta-analysis should include all of the available studies. The inherent conflicts in the provision of IPD were in line with the barriers to data sharing described in the literature, including concerns about protecting subject confidentiality and anonymity, lack of time, and unavailable or unusable datasets ([@bib0135]). It was not possible to explore potential sources of heterogeneity as planned given the lack of comparison groups to estimate the hazard ratios for each study. Some datasets included children while others included only adults, and all studies were conducted in a single country. The meta-analysis also did not include sufficient IPD from countries where the TcI *Trypanosoma cruzi* lineage may be prevalent ([@bib0270]).

The electronic searches were updated on August 28, 2017 to find new studies published since the last search. At that time, three potentially eligible studies reporting serological outcomes (two studies including adults living in Argentina and Spain, and one study including children living in Guatemala) were identified; these will be considered in future updates.

The survival analyses may be useful in regard to current recommendations for the clinical management of chronic *Trypanosoma cruzi* infection. Factors such as the age of the patient attending the clinical appointment and the age at treatment (time elapsed between treatment and clinical assessment), the country of origin (or the country where the infection was acquired), and the complementary assessment of conventional serology and PCR results are critical to monitoring after treatment.

The use of participant-level data was intended to overcome the pragmatic constraints of a new follow-up study, such as the long time between exposure to anti-trypanosomal drugs and seroreversion, the need for appropriate sample sizes for children and adults, and adequate rates of follow-up. It is hoped that this study provides an encouraging example of the importance of anonymizing and sharing IPD for secondary analysis. This strategy may decrease the burden on research resources through the meaningful reuse of existing data.

The next steps will be to determine the course of molecular and parasitological tests after treatment during chronic *Trypanosoma cruzi* infection and to conduct a new analysis using available IPD according to the standard definition of cure (seroreversion defined as having negative results for at least two different serology techniques) as the primary result. The time period covered will likely be that during which healthcare providers expect to make decisions based on official guidelines, e.g., up to 3 years. The ultimate goal is to provide a monitoring tool to help in the assessment of treatment in chronically infected patients.

Annexes A--C. Supplementary data {#sec0065}
================================
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[^1]: ELISA, enzyme-linked immunosorbent assay; IIF, indirect immunofluorescence assay; IHA, indirect hemagglutination assay; IPD, individual participant data; NK, not known; PCR, polymerase chain reaction; XD, xenodiagnosis.

[^2]: The study identification includes surname of primary author and year of publication.

[^3]: The estimate of the total number of subjects was based on the test with the best number of individual participant data.

[^4]: CI, confidence interval; ELISA, enzyme-linked immunosorbent assay; IIF, indirect immunofluorescence assay; IHA, indirect hemagglutination assay; HR, hazard ratio.

[^5]: The *p*-value corresponds to the effect of the interaction obtained from the adjusted Cox proportional hazards model.
